Spyre Therapeutics is developing next-generation antibody therapies and rational therapeutic combinations specifically for Inflammatory Bowel Disease (IBD) to enhance treatment efficacy and dosing convenience. The company aims to provide patients with improved therapeutic options that address the limitations of current IBD treatments.
Funding
$200M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for Inflammatory Bowel Disease (IBD) often have limited efficacy and require frequent dosing, which can be inconvenient for patients. These limitations highlight the need for improved therapeutic options that offer better efficacy and more convenient administration.
Solution
Spyre Therapeutics is developing next-generation antibody therapies and rational therapeutic combinations specifically designed for IBD. The company focuses on engineering potential best-in-class antibodies and employing precision immunology approaches to create IBD therapies with enhanced efficacy and improved dosing convenience. By addressing the shortcomings of existing treatments, Spyre aims to provide patients with more effective and convenient therapeutic options.
Target Audience
The primary target audience includes patients suffering from Inflammatory Bowel Disease (IBD) and the healthcare professionals who treat them, such as gastroenterologists.
Features
- Development of next-generation antibodies targeting key IBD pathways.
- Rational therapeutic combinations to enhance treatment efficacy.
- Precision immunology approaches for targeted drug delivery and personalized treatment strategies.
- Focus on improving dosing convenience to enhance patient compliance.